Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients

AstraZeneca

Status: Completed

Conditions: Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01164397

NIS-CME-CRE-2010/1

DM-CRESTOR-0003 (Other Identifier)

Details and patient eligibility

About

The aim of this study is to evaluate the effectiveness of Rosuvastatin versus Ezetimibe/Simvastatin in dyslipidemic patients treated for at least 8 weeks.

Enrollment: 268 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Dislipidemic population treated with rosuvastatin or ezetimibe/simvastatin for at least for 8 weeks
• Who have completed at least 80% of the treatment
• To have determinations at least of CT, TG C-LDL and CHDL before starting treatment and after 8 weeks of taking the medicine

Exclusion criteria

• Initiating different therapy lipid lowering to Rosuvastatin or Ezetimibe/Simvastatin

Trial design

268 participants in 1 patient group

Dislipidemic Population

Description:

People with high levels of total cholesterol, LDL, C-HDL and triglycerides